Sermorelin Side Effects: What Studies and the Old Label Show

    Sermorelin Side Effects: What Studies and the Old Label Show

    Sermorelin's main side effect is injection-site pain or redness in about 1 in 6 people. Label rates, antibodies, thyroid risk, FDA status, when to see a doctor.

    Written by Dr. Andrii Kaleniuk. Updated November 19, 2026.

    The most common side effect of sermorelin is an injection-site reaction, such as pain, swelling or redness, which affected about 1 in 6 patients in the trials behind the original FDA-approved product, Geref. Other reactions, including headache, flushing, trouble swallowing, dizziness, hyperactivity, sleepiness and hives, each occurred in fewer than 1% of people. Sermorelin is a lab-made copy of part of growth hormone-releasing hormone (GHRH), the brain signal that tells the pituitary gland to release growth hormone. Geref was approved for children with growth hormone deficiency, but its maker discontinued it in 2008; in 2013 the FDA found it was not withdrawn for safety or effectiveness reasons. As of November 2026 there is no FDA-approved sermorelin product in the US, and what is sold is compounded, meaning mixed by a pharmacy without FDA review of the final product. This guide covers the label's side-effect numbers, what small studies in adults found, the antibody and thyroid warnings, where sermorelin stands with the FDA, and when to call a doctor. It contains no dosing information.

    Sermorelin Side Effects: The Short Answer

    1. 1Most common: injection-site pain, swelling or redness in about 1 in 6 patients on the original Geref label.
    2. 2Uncommon (under 1% each): headache, flushing, trouble swallowing, dizziness, hyperactivity, sleepiness, hives.
    3. 3Antibodies: "a large proportion" of patients developed anti-GRF antibodies, with unclear significance.
    4. 4Thyroid: hypothyroidism occurred in 6.5% of patients in clinical studies, so the label advised checking thyroid function.
    5. 5Not FDA-approved now: Geref was discontinued in 2008; the FDA said in 2013 this was not for safety reasons.
    6. 6Compounded products: not FDA-reviewed, and long-term safety data in adults are lacking.

    What Is Sermorelin, and Was It Ever FDA-Approved?

    Yes. According to a 2013 Federal Register notice, the FDA approved Geref Diagnostic, a version for testing how well the pituitary releases growth hormone, on December 28, 1990. It approved Geref (sermorelin acetate) vials on September 26, 1997, for treating children with idiopathic growth hormone deficiency (deficiency with no identified cause) and growth failure. Both were made by EMD Serono. Neither was approved for anti-aging, body composition or athletic performance in adults. How sermorelin differs from other growth hormone-releasing peptides is explained in sermorelin vs ipamorelin.

    Why Was Geref Taken Off the Market?

    EMD Serono told the FDA in letters dated July 11 and December 2, 2008 that it was discontinuing the products and asked for the approvals to be withdrawn. The FDA withdrew both approvals effective June 18, 2009. After a 2012 citizen petition, the FDA determined in a notice published March 4, 2013 that the products "were not withdrawn for reasons of safety or effectiveness." They stay on the FDA's list of discontinued drugs, and generic versions referencing them "may be approved." We found no record that any generic was approved after that. A 2006 review by Walker in Clinical Interventions in Aging gave one author's explanation: that Geref "could not compete with rhGH," meaning injected growth hormone itself. That is a commercial reason, not an FDA finding.

    What Side Effects Did the Original Geref Label List?

    The label figures below come from a copy of the Geref prescribing information hosted by RxList; we could not find the original on an FDA or DailyMed page. In clinical trials, 350 patients received the drug. Injection-site reactions were the most common treatment-related event, and 3 of the 350 patients stopped because of them. When the diagnostic version was given into a vein, reported reactions included flushing, injection-site reactions, nausea, headache, vomiting, altered taste, pallor and chest tightness. Current drug references, Drugs.com (updated June 2026) and Mayo Clinic (updated February 2026), list the same reactions.

    Side effects on the original Geref (sermorelin acetate) label

    Effect
    How often
    Notes

    Injection-site pain, swelling or redness

    About 1 in 6 patients

    Most common treatment-related event

    Stopped because of injection reactions

    3 of 350 patients (under 1%)

    350 patients exposed in trials

    Headache, flushing, trouble swallowing, dizziness

    Under 1% each

    Listed as uncommon

    Hyperactivity, sleepiness, hives

    Under 1% each

    Listed as uncommon

    Hypothyroidism

    6.5% in clinical studies

    Label advised checking thyroid function

    Anti-GRF antibodies

    "A large proportion" of patients

    Clinical significance unclear; growth not apparently affected

    Generalized allergic reactions

    None reported

    Contraindicated with known sensitivity

    How Common Are Injection-Site Reactions With Sermorelin?

    On the label, about 1 in 6 patients, or roughly 17%, had pain, swelling or redness where the drug was injected. Most did not stop treatment: only 3 of 350 patients did. A 1999 review in BioDrugs of sermorelin in children likewise described it as well tolerated, with "transient facial flushing and pain at injection site" as the most common events. Those figures come from a regulated, sterile product. A compounded or online product can differ in purity and sterility, so redness that spreads, warmth, pus or fever should be treated as a possible infection rather than a normal reaction.

    Can Sermorelin Cause Antibodies, Allergic Reactions or Thyroid Problems?

    Antibodies: the label states that "a large proportion of patients develop anti-GRF antibodies," meaning the immune system makes antibodies against the drug. Their clinical significance was unclear. No generalized allergic reactions were reported, and the antibodies did not appear to affect growth in the children treated.

    Allergy: the label lists known sensitivity to sermorelin as a contraindication, a reason not to use it. Hives were reported in under 1% of patients, and Drugs.com and Mayo Clinic list itching and trouble swallowing among reactions to report.

    Thyroid: hypothyroidism, an underactive thyroid, occurred in 6.5% of patients in clinical studies, and the label advised monitoring thyroid function. Questions about other hormone effects from growth hormone peptides are covered in does ipamorelin raise cortisol or prolactin.

    Does Sermorelin Cause Water Retention or Joint Pain?

    These effects are not on the Geref label. Healthy Male, a government-funded Australian men's health organization, says that keeping growth hormone or IGF-1 raised over time carries risks including fluid retention, joint pain and, with prolonged elevation, possible effects on insulin sensitivity. It presents these as risks of raised growth hormone in general, not as measured sermorelin side effects, and gives no study citations. Because these effects are known for drugs that raise growth hormone, it is reasonable to watch for swelling of the hands or feet and joint aches, but there are no reliable figures for sermorelin itself. Similar growth hormone-class effects are discussed in tesamorelin side effects and CJC-1295 and ipamorelin side effects.

    What Side Effects Showed Up in Studies of Older Adults?

    Evidence in adults is thin. In a 1997 study in the Journal of Clinical Endocrinology and Metabolism, Khorram, Laughlin and Yen gave 19 adults aged 55 to 71 nightly injections for 16 weeks after a 4-week placebo period. They reported that "the only adverse side-effect was transient hyperlipidemia," a temporary rise in blood fats, "which resolved by the end of the study." A second paper on the same group, looking at immune measures, reported no adverse effects.

    There is an important caveat: that study used a closely related GHRH analog, not sermorelin acetate itself, so its results may not transfer exactly. With 19 people and 16 weeks, it also could not detect rare or long-term effects. Healthy Male notes that no published systematic reviews or randomized controlled trials support sermorelin for anti-aging or body composition in healthy people, and that no peer-reviewed trials have shown it improves athletic performance. We found no long-term safety or cancer data for sermorelin in adults.

    Is Compounded Sermorelin Legal, and Where Is It on the FDA's Lists?

    Sermorelin's status is unsettled. Pharmacies compounding under section 503A of US drug law may use certain bulk ingredients, and the FDA sorts nominated ingredients into categories: Category 1 (may be eligible; the FDA does not intend to act while it reviews them), Category 2 (significant safety risks) and Category 3 (insufficient information). According to the FDA's category list updated May 14, 2026, sermorelin is not in any of the three. In 2023 the FDA placed 19 peptide-related substances in Category 2; it removed seven of them on April 15, 2026, and an FDA advisory committee recommended six of those for the bulks list in July 2026. Sermorelin was not among any of these. The wider rule changes are summarized in FDA peptide rules in 2026.

    The Alliance for Pharmacy Compounding, a trade group, says sermorelin can be compounded under 503A because it is "part of an FDA approved drug product," and that it is not a biologic because it has fewer than 40 amino acids. That is the trade group's reading; we found no FDA statement confirming it after Geref's approval was withdrawn. Either way, compounded sermorelin is not FDA-approved, so the FDA has not reviewed any compounded product's safety, quality or effectiveness.

    Sermorelin regulatory timeline

    Date
    Event

    Dec 28, 1990

    Geref Diagnostic approved (pituitary testing)

    Sep 26, 1997

    Geref approved for children with idiopathic GH deficiency

    2008

    EMD Serono discontinues Geref and asks for withdrawal

    Jun 18, 2009

    FDA withdrawal of both approvals takes effect

    Mar 4, 2013

    FDA: "not withdrawn for reasons of safety or effectiveness"

    2023

    FDA places 19 peptide-related substances in Category 2; sermorelin not among them

    Apr 15, 2026

    FDA removes 7 peptides from Category 2; sermorelin not among them

    May 14, 2026

    FDA 503A category list: sermorelin not in Category 1, 2 or 3

    Jul 23-24, 2026

    FDA advisory committee backs 6 peptides for the bulks list; sermorelin not among them

    Are Compounded or "Research" Sermorelin Products Riskier Than Geref Was?

    They carry risks Geref did not. Geref was made under FDA oversight, and its side-effect rates come from that product. A compounded version has not been reviewed by the FDA for quality, and a product sold online as "research use only" is not intended for people at all and may not match its label. The figures in this article therefore describe the best case. Why the research-use-only label offers no protection is explained in research use only peptides. Competitive athletes should also check anti-doping rules, outlined in peptides banned by WADA.

    Who Should Not Use Sermorelin?

    1. 1Anyone with a known sensitivity to sermorelin (a label contraindication).
    2. 2People with untreated hypothyroidism: the label said it can jeopardize the response and advised checking thyroid levels before and during treatment.
    3. 3People whose growth hormone deficiency is caused by a brain (intracranial) lesion; the label did not recommend it for them.
    4. 4Pregnant people: the label listed Pregnancy Category C, meaning risk could not be ruled out.
    5. 5Healthy adults seeking anti-aging or muscle effects, for whom no randomized trials show benefit.

    When to Talk to Your Doctor

    1. 1Trouble swallowing, hives, itching or swelling of the face, which Drugs.com and Mayo Clinic list as reactions to report.
    2. 2Dizziness, flushing or headache that does not settle.
    3. 3Spreading redness, warmth, pus or fever around an injection site.
    4. 4Tiredness, feeling cold or weight gain that could suggest an underactive thyroid.
    5. 5You are pregnant or planning pregnancy.

    What to Do Next: Questions to Ask Your Doctor

    1. 1Do I have a diagnosed condition that sermorelin, or an approved alternative, is meant to treat?
    2. 2Where does this product come from, and has its pharmacy been inspected?
    3. 3Should my thyroid function be checked before and during use?
    4. 4Which side effects should make me stop and call you?
    5. 5What evidence supports using it for my goal, and how will we judge whether it is working?

    Keep a simple log of any injection-site reactions, headaches or sleep changes, and bring it to appointments. Comparable side-effect profiles for related peptides are in ipamorelin side effects.

    The Bottom Line

    On the original Geref label, sermorelin's main side effect was an injection-site reaction in about 1 in 6 patients, with other reactions each under 1%, plus antibodies in many patients and hypothyroidism in 6.5%. Geref was discontinued for business reasons, not safety ones, according to the FDA. Today's compounded products are not FDA-reviewed, sermorelin sits on none of the FDA's 503A category lists, and adult safety data are limited to small, short studies, including one using an analog. Those gaps matter more than the reassuring label numbers.

    FAQ

    Injection-site pain, swelling or redness, in about 1 in 6 patients on the original Geref label. Headache, flushing, dizziness and other reactions each occurred in under 1%.

    It is not on the Geref label. Fluid retention is a known effect of raising growth hormone and some sites list it, but there are no reliable figures for sermorelin.

    Not currently. Geref was approved in 1990 and 1997, then discontinued in 2008. As of November 2026, sermorelin products in the US are compounded and not FDA-approved.

    Its maker, EMD Serono, discontinued Geref in 2008. In 2013 the FDA determined it was not withdrawn for reasons of safety or effectiveness.

    Unknown. We found no long-term safety or cancer data in adults. The adult studies available were small and lasted about 16 weeks.

    Yes. Hypothyroidism occurred in 6.5% of patients in Geref's clinical studies, and the label advised monitoring thyroid function.

    Sources

    1. 1Federal Register notice on GEREF and GEREF Diagnostic (Vol. 78, No. 42, March 4, 2013), US Food and Drug Administration, 2013
    2. 2Geref (sermorelin acetate) label text, side effects section, RxList (copy of the original label)
    3. 3FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, US Food and Drug Administration, May 14, 2026
    4. 4FDA. Bulk drug substances used in compounding under section 503A of the FD&C Act, US Food and Drug Administration, 2026
    5. 5Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, BioDrugs, 1999
    6. 6Khorram O, Laughlin GA, Yen SSC. Study of a GHRH analog in adults aged 55 to 71, Journal of Clinical Endocrinology and Metabolism, 1997;82(5), doi:10.1210/jcem.82.5.3943
    7. 7Khorram O, et al. Immune endpoints in the same cohort, Journal of Clinical Endocrinology and Metabolism, 1997
    8. 8Walker RF. Review of sermorelin, Clinical Interventions in Aging, 2006
    9. 9Drugs.com. Sermorelin (Injection), Drugs.com, June 10, 2026
    10. 10Mayo Clinic. Sermorelin drug information, Mayo Clinic, February 1, 2026
    11. 11Polsinelli. Client publication on FDA actions on peptide compounding, Polsinelli, April 22, 2026
    12. 12Holland & Knight. Alert on the July 2026 FDA advisory committee peptide votes, Holland & Knight, August 4, 2026
    13. 13Healthy Male. Sermorelin: what the evidence shows, Healthy Male (Australia), accessed November 2026
    14. 14Alliance for Pharmacy Compounding. Statement on peptide compounding, Alliance for Pharmacy Compounding (trade group), 2022

    This article summarizes regulatory documents and published research for general information and is not medical advice. Sermorelin is not currently FDA-approved, and nothing here is a recommendation to use it.

    Dr. Andrii Kaleniuk

    Author

    Published November 19, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    CJC-1295 + Ipamorelin for Muscle Growth: Real Gains or Just GH Hype?